Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0–B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Published:2014-12 Issue:12 Volume:109 Page:1891-1899
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Feng Xiaobin,Xu Ruocai,Du Xilin,Dou Kefeng,Qin Xiao,Xu Jun,Jia Weidong,Wang Zhiming,Zhao Hongzhi,Yang Shufa,Guo Chenyang,Liu Tianqi,Ma Kuansheng

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2014343.pdf

Reference33 articles.

1. Trends in the leading causes of death in the United States, 1970-2002.;Jemal;JAMA,2005

2. Primary liver cancer: worldwide incidence and trends.;Bosch;Gastroenterology,2004

3. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.;Gomaa;World J Gastroenterol,2008

4. Management of hepatocellular carcinoma.;Bruix;Hepatology,2005

5. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.;Chen;Ann Surg,2006

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transarterial Chemoembolization Combined with Lenvatinib Plus Sequential Microwave Ablation for Large Hepatocellular Carcinoma Beyond Up-to-Seven Criteria: A Retrospective Cohort Study;Academic Radiology;2024-07

2. Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma;Biomedicines;2024-06-27

3. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma;Journal of Translational Medicine;2024-06-06

4. New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma;Chinese Journal of Cancer Research;2024

5. Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial;Cancer Medicine;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3